MynxGrip Vascular Closure Device (5F, 6F/7F); Mynx Control Vascular Closure Device (5F, 6F/7F); Mynx Control Venous Vasc
Cordis US Corporation · Decision date Jul 23, 2025
What did the FDA decide?
FDA records P040044/S110 as a supplement to PMA P040044, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 23, 2025.
FDA approval order statement
conducting routine Bioburden testing at an alternate, in-house test site
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 23, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P040044/S110
- Regulatory pathway
- PMA supplement
- Applicant
- Cordis US Corporation
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Jul 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Cordis US Corporation
- Product code
- MGB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P040044/S110 received
Application receipt date recorded by FDA.
P040044/S110 · FDA decision
30-Day Notice
P040044/S111 · Related supplement
Mynx Control Vascular Closure Device (5F, 6F/7F)
P040044/S113 · Related supplement
Cordis Mynx Vascular Closure Portfolio (VCP): MynxGrip, Mynx Control, and Mynx Control Venous Vascular Closure
Timeline entries are records held by MedtechLedger for P040044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Mynx Control Vascular Closure Device (5F, 6F/7F)P040044/S111 | Cordis US Corporation | PMA supplement | Mar 31, 2026 | FDA |
| Cordis US Corporation | PMA supplement | May 14, 2026 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cordis US Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 14201 NW 60th Ave., Miami Lakes, FL, 33014
Sources and methodology
- Original FDA record: P040044/S110
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



